GLP-1 Medications in Tokyo: Wegovy, Ozempic, and What English Speakers Need to Know
If you are living in Tokyo or visiting Japan and hoping to access GLP-1 receptor agonist medications such as Wegovy or Ozempic for weight management, you are not alone — and the landscape here is genuinely different from what many readers encounter in their home countries.
This article explains what is currently available in Japan, what the regulations mean for you in practice, and which complementary approaches are offered through English-speaking medical channels in Tokyo.
What you’ll learn in this article:
- What GLP-1 receptor agonists are and how they work for weight loss
- The current regulatory and availability status of Wegovy and Ozempic in Japan
- Realistic alternatives and complementary treatments accessible to English speakers in Tokyo
- Who is a suitable candidate and who should exercise caution
- Where to access English-language medical consultations in Tokyo to discuss your options
Have a question about this treatment?
Message us on LINE or WhatsApp — our English-speaking team usually replies the same day.
What Are GLP-1 Receptor Agonists?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after eating. GLP-1 receptor agonists are synthetic medications that mimic this hormone, stimulating insulin release, reducing appetite, and slowing gastric emptying — the speed at which the stomach empties food into the intestine. The practical effect is that users feel full sooner and remain satisfied for longer, which tends to reduce overall caloric intake.
Semaglutide is the active compound in both Ozempic (approved for type 2 diabetes) and Wegovy (approved at a higher dose specifically for chronic weight management). Both are administered as a once-weekly subcutaneous injection. Tirzepatide, marketed as Mounjaro, is a newer dual-agonist targeting both GLP-1 and GIP receptors and has demonstrated even greater weight-loss outcomes in clinical trials.
How Effective Are These Medications?
Clinical evidence is substantial. The STEP 1 trial, published in The New England Journal of Medicine (2021), reported that participants receiving once-weekly semaglutide 2.4 mg (the Wegovy dose) achieved a mean body-weight reduction of approximately 14.9% over 68 weeks, compared with 2.4% in the placebo group. Studies using tirzepatide suggest even greater average reductions — some participants in the SURMOUNT-1 trial lost more than 20% of body weight over approximately 72 weeks.
These figures represent population averages; individual results vary based on baseline weight, diet, physical activity, and metabolic factors. Medication alone is not considered a standalone solution — clinical guidelines consistently recommend these treatments as adjuncts to lifestyle modification.
Availability of Wegovy and Ozempic in Japan
Japan’s regulatory framework for GLP-1 medications has evolved significantly in recent years, but there are important nuances that directly affect English-speaking residents and visitors.
Ozempic (Semaglutide for Diabetes)
Ozempic received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of type 2 diabetes and is available through Japanese hospitals and clinics under the national health insurance system — but only when prescribed for diabetes. Prescribing it off-label solely for weight loss in patients without a diabetes diagnosis is a grey area and varies by institution.
Wegovy (Semaglutide for Weight Management)
Wegovy received PMDA approval for weight management in Japan in March 2023, making Japan one of the earlier markets in Asia to grant this approval. However, supply constraints and healthcare system logistics have meant that access has been uneven. Many general practitioners and internal medicine clinics offer it through self-pay (jishu shinryo) pathways, particularly at weight-management clinics and online telemedicine services within Japan.
Tirzepatide (Mounjaro)
Tirzepatide received PMDA approval for type 2 diabetes in Japan in 2023. As of the time of writing, its approval specifically for obesity management in Japan is pending or in process; the situation may have progressed since this article was prepared, and readers should confirm current status with a licensed Japanese physician.
Key Practical Considerations for English Speakers
Most weight-management clinics in Japan operate entirely in Japanese, making navigation challenging without language support. Self-pay pricing varies considerably between providers. Additionally, Japan has been affected by global shortages of semaglutide at various points, meaning even clinics that offer Wegovy may face stock limitations. A consultation with an English-speaking physician familiar with the Japanese regulatory environment is strongly advisable before pursuing any GLP-1 prescription here.
Dr. Karibe’s Note
Many of our international patients are surprised to find that GLP-1 medications, while technically available in Japan, are not straightforwardly accessible through English-language channels. A common question I receive is whether there are complementary body-contouring or metabolic support treatments that can be explored during a consultation in English.
At BIOTOPE CLINIC, we do discuss body concerns holistically — and where GLP-1 prescribing falls outside our surgical and aesthetic scope, we aim to point patients toward appropriate referral pathways while addressing areas where we can genuinely help.
Realistic Cost Expectations in Tokyo
GLP-1 medications are self-pay for weight management purposes in Japan (they are not covered by national health insurance in this context). Costs vary considerably between providers.
As a general market reference, monthly self-pay costs for semaglutide at weight-management clinics in Tokyo have ranged from approximately ¥30,000 to ¥80,000 per month depending on dosage and provider. These figures are based on general market observation and are not clinic prices — they represent the broader Tokyo landscape. Initial consultation fees at Japanese weight clinics typically range from around ¥3,000 to ¥10,000.
At BIOTOPE CLINIC in Shirokanedai, an initial consultation is priced at ¥3,300, and a surgical or specialist consultation with Dr. Karibe is ¥2,200. This provides an accessible starting point for English speakers who wish to discuss their weight or body concerns with a board-certified specialist before deciding on any treatment path.
For body contouring that does not depend on medication availability, options such as fat-dissolving injections are available at BIOTOPE CLINIC for targeted areas. Liposuction of the cheek and jawline area is available from ¥280,000 per area. These are distinct from systemic weight-loss medication but may be relevant for readers interested in specific contour concerns. For an accurate quote, we recommend booking a consultation.
Have a question about this treatment?
Message us on LINE or WhatsApp — our English-speaking team usually replies the same day.
Alternatives and Complementary Approaches in Tokyo
For English speakers who cannot readily access GLP-1 medications or who prefer to explore complementary approaches, there are several options available through English-language medical channels in Tokyo.
Preventive Medicine and Metabolic Support at BIOTOPE CLINIC
BIOTOPE CLINIC’s preventive medicine programme includes orthomolecular (nutritional) therapy, gut microbiome analysis, genetic testing, NMN supplementation, and IV drip therapy including vitamin C and glutathione infusions.
While none of these replicate the pharmacological mechanism of GLP-1 agonists, they address metabolic foundations — nutrient status, gut health, and cellular energy — that support broader wellness goals. These are treatments available at BIOTOPE CLINIC in Shirokanedai; feel free to ask about them during a consultation with Dr. Karibe.
Body Contouring Procedures
For patients who have already achieved meaningful weight reduction — whether through GLP-1 medications or lifestyle changes — and are seeking to address remaining areas of localised fat or skin laxity, BIOTOPE CLINIC offers surgical and non-surgical body contouring options. HIFU (High-Intensity Focused Ultrasound) for skin tightening is available from ¥25,000 to ¥110,000. Thread lifts using Tesslift threads are available from ¥48,000 per thread. These are not weight-loss treatments but may complement a weight management journey.
What People Often Get Wrong About GLP-1 Medications
Misconception 1: Ozempic and Wegovy are the same medication.
Although both contain semaglutide, they are different products at different approved doses. Ozempic (up to 1 mg or 2 mg depending on the indication) is approved for type 2 diabetes management. Wegovy (2.4 mg) is approved specifically for chronic weight management. Using Ozempic off-label for weight loss is not the same as receiving Wegovy under its approved indication — and in Japan, this distinction matters for how a physician can legally and responsibly prescribe.
Misconception 2: Stopping the medication maintains the results permanently.
Clinical evidence indicates that a significant proportion of weight lost during GLP-1 therapy is regained after discontinuation if lifestyle changes are not sustained. The STEP 4 extension study found that participants who discontinued semaglutide after 20 weeks regained a substantial portion of lost weight over the following year. These medications are generally considered ongoing therapies rather than short-course treatments, which has significant cost and logistical implications for expatriates or medical tourists who are only in Japan temporarily.
Who Is a Good Candidate — and Who Should Exercise Caution
Potentially Suitable Candidates
- Adults with a BMI of 27 or above (Japanese clinical thresholds may differ from Western guidelines) who have not achieved adequate results through diet and exercise alone
- Individuals with weight-related health conditions such as hypertension, dyslipidaemia, or pre-diabetes
- Patients committed to concurrent lifestyle modification and willing to engage in ongoing medical supervision
Those Who Should Exercise Caution or Avoid
- Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — these are contraindications for semaglutide
- Those with a history of pancreatitis
- Pregnant or breastfeeding individuals
- Patients with severe gastrointestinal conditions
- Anyone seeking a short-stay solution: GLP-1 medications require ongoing supervision, and discontinuing abruptly without a transition plan is not advisable
GLP-1 vs. Body Contouring: Understanding the Difference
| Factor | GLP-1 Medications (Wegovy/Ozempic) | Body Contouring (Liposuction, HIFU, Thread Lift) |
|---|---|---|
| Mechanism | Systemic hormonal appetite suppression; metabolic | Localised fat removal or skin tightening |
| Weight reduction | Significant total body weight reduction possible | Not a weight-loss treatment; targets contour |
| Suitable for | Overweight/obese patients with health risk factors | Patients near target weight with localised concerns |
| Duration of effect | Ongoing; weight may return after stopping | Long-lasting for fat removal; varies for tightening |
| English access in Tokyo | Limited; mostly Japanese-language clinics | Available in English at BIOTOPE CLINIC, Shirokanedai |
| Supervision required | Ongoing physician oversight essential | Pre- and post-operative care; less frequent follow-up |
| Cost range (Tokyo, self-pay) | Approx. ¥30,000–¥80,000/month (market range) | Varies by procedure; see clinic price list |
Where to Get GLP-1 Advice and Body Consultations in Tokyo (English)
Within our clinic group, English-speaking consultations are handled at BIOTOPE CLINIC in Shirokanedai (Minato-ku, Tokyo) by Dr. Jun Karibe. Our sister clinic, Kojimachi Dermatology and Plastic Surgery Clinic in Ichigaya (Chiyoda-ku), serves as the group’s main office and handles Japanese-language insurance-covered dermatology — it is not currently set up for English-speaking consultations. For all English enquiries, including body contouring, preventive medicine, or general questions about navigating weight management in Tokyo, the appropriate contact is BIOTOPE CLINIC. Bookings and enquiries in English: LINE or WhatsApp.
In Dr. Karibe’s clinical experience at BIOTOPE CLINIC, expatriates and international visitors frequently arrive having already started GLP-1 treatment abroad and are seeking support for the cosmetic sequelae — such as facial volume loss (sometimes called “Ozempic face”) or residual localised fat — or wish to understand their options in a language they feel confident in. These consultations are welcomed and can address both the aesthetic and the general wellness dimension of the patient’s concerns.
Frequently Asked Questions
- Q. Can a tourist or short-term visitor to Japan get Wegovy prescribed here?
- It is technically possible for a visitor to be seen by a physician in Japan and receive a prescription, but in practice most weight-management clinics offering GLP-1 medications are Japanese-language services. Supply can also be inconsistent. A short-term visitor is generally not an ideal candidate for starting GLP-1 therapy in Japan, as these medications require ongoing monitoring and dose titration over many weeks. We recommend consulting your home-country physician before travelling if this is your goal.
- Q. What is “Ozempic face” and can it be treated?
- “Ozempic face” is an informal term describing facial volume loss — particularly in the cheeks and temples — that some patients experience during rapid weight reduction associated with GLP-1 therapy. It is not unique to Ozempic; it occurs with any significant weight loss. Treatment options include hyaluronic acid filler, which is available at BIOTOPE CLINIC from ¥66,000–¥88,000 per syringe, as well as other volume-restoration approaches that Dr. Karibe can discuss during a consultation.
- Q. Is BIOTOPE CLINIC able to prescribe GLP-1 weight-loss medications?
- BIOTOPE CLINIC is a cosmetic and plastic surgery clinic, and GLP-1 prescribing for weight management falls outside its primary clinical scope. However, consultations are available in English to help you understand your body contouring options, address concerns related to weight-related aesthetic changes, and where appropriate, assist with referral guidance. The preventive medicine programme — including nutritional therapy and gut microbiome analysis — is also available to support broader wellness goals.
- Q. Are there Japanese insurance-covered weight management options?
- National health insurance in Japan does not cover semaglutide or tirzepatide for weight management at present; these are self-pay treatments in this context. Ozempic may be covered under insurance when prescribed specifically for type 2 diabetes by an internist or endocrinologist. Kojimachi Dermatology and Plastic Surgery Clinic handles insurance-covered dermatology and plastic surgery for Japanese-speaking patients; English speakers are directed to BIOTOPE CLINIC in Shirokanedai.
- Q. How do I contact BIOTOPE CLINIC in English?
- The most direct route for English-speaking patients is via LINE or WhatsApp. The English-speaking team at BIOTOPE CLINIC in Shirokanedai handles all international enquiries and can assist with appointment booking, treatment questions, and pre-consultation information.
Have a question about this treatment?
Message us on LINE or WhatsApp — our English-speaking team usually replies the same day.
Summary
GLP-1 receptor agonist medications — including Wegovy and Ozempic — are available in Japan with a valid prescription, but accessing them through English-language channels requires some navigation. Wegovy received PMDA approval for weight management in 2023, yet supply and language barriers remain practical challenges for expatriates and visitors.
Clinical evidence supports meaningful weight reduction in suitable candidates, but these medications are long-term commitments rather than short-course solutions, and discontinuing without a plan tends to result in weight regain.
For English-speaking patients in Tokyo who wish to discuss body concerns, facial volume changes related to weight loss, or complementary aesthetic and preventive medicine options, BIOTOPE CLINIC in Shirokanedai offers consultations in English with Dr. Jun Karibe, a board-certified plastic surgeon. The clinic’s sister facility, Kojimachi Dermatology and Plastic Surgery Clinic in Ichigaya, serves the group’s Japanese-language insurance patients and operates as the group’s main office.
If you have questions about GLP-1 medications, weight-related aesthetic concerns, or body contouring in Tokyo, English-speaking consultations are handled at BIOTOPE CLINIC in Shirokanedai (Minato-ku, Tokyo) by Dr. Karibe. Our sister clinic Kojimachi Dermatology and Plastic Surgery Clinic in Ichigaya (Chiyoda-ku) handles Japanese-language insurance dermatology. English enquiries: LINE or WhatsApp.
24/7 Consultation & Booking
Book a Consultation or Treatment
Our English-speaking team responds via LINE or WhatsApp — usually the same day.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205–216.
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138–150.
- Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Approval information for semaglutide (weight management indication). 2023.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414–1425.
Related Articles
You may also find these articles useful.
- English-Speaking Dermatologist Tokyo: Fees & Costs
- English Speaking Dermatologist Tokyo: Complete Guide
- Skin Clinic Tokyo for Foreigners: Finding English Support
- IV Vitamin Drip Tokyo: Wellness Treatment for Expats
SUPERVISED BY
Dr. Jun Karibe
MD
Director
Education & Career
Certifications
Awards
